Magle Group and Sirtex Medical extend exclusive partnership to accelerate global value creation in embolisation

13/01/2026

Magle Group and Sirtex Medical have signed an extended long term exclusive agreement, further deepening their strategic partnership in the entire field of embolisation. The agreement is intended to accelerate global market expansion, including the United States, while materially reducing execution risk of entering new markets and enhancing long-term value creation through new indications and product lines.

Under the extended agreement, Sirtex will take the lead in the United States and all other new markets on clinical programmes and market entry activities, with Magle supporting through its manufacturing capabilities and DSM (degradeable starch microspheres) technology platform. This structure is designed to shorten time to market, improve capital efficiency and provide a more scalable and predictable route to revenue growth.

The strengthened collaboration combines Magle’s proprietary degradable embolisation technologies with Sirtex’s established global clinical and commercial infrastructure, creating a strong platform for accelerated growth and continued innovation within embolisation.

Aaron Wong, Interim CEO of Magle Group, said: “This agreement significantly strengthens our ability to scale embolisation globally in a capital-efficient manner. By having Sirtex lead US clinical execution and market entry, we reduce cost and risk while accelerating our ability to unlock new markets, indications and long-term shareholder and patient value.”

Matthew Schmidt, CEO of Sirtex Medical, said: “We are pleased to further strengthen our partnership with Magle. By combining Magle’s innovative embolisation technologies with Sirtex’s global clinical and commercial capabilities, we see a compelling opportunity to accelerate growth, expand the reach of embolisation therapies and deliver meaningful value for patients and physicians.”